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Abstract
Background: Pancreatic polypeptide (PP) is a potent anti-obesity agent known to inhibit food intake in the absence of
nausea, but the mechanism behind this process is unknown.
Methodology/Principal Findings: Here we demonstrate that in response to i.p. injection of PP in wild type but not in Y4
receptor knockout mice, immunostaining for the neuronal activation marker c-Fos is induced specifically in neurons of the
nucleus tractus solitarius and the area postrema in the brainstem, notably in cells also showing immunostaining for tyrosine
hydroxylase. Importantly, strong c-Fos activation is also detected in the arcuate nucleus of the hypothalamus (ARC),
particularly in neurons that co-express alpha melanocyte stimulating hormone (a-MSH), the anorexigenic product of the
proopiomelanocortin (POMC) gene. Interestingly, other hypothalamic regions such as the paraventricular nucleus, the
ventromedial nucleus and the lateral hypothalamic area also show c-Fos induction after PP injection. In addition to c-Fos
activation, PP injection up-regulates POMC mRNA expression in the ARC as detected by in situ hybridization. These effects
are a direct consequence of local Y4 signaling, since hypothalamus-specific conditional Y4 receptor knockout abolishes PP-
induced ARC c-Fos activation and blocks the PP-induced increase in POMC mRNA expression. Additionally, the hypophagic
effect of i.p. PP seen in wild type mice is completely absent in melanocortin 4 receptor knockout mice.
Conclusions/Significance: Taken together, these findings show that PP reduces food intake predominantly via stimulation
of the anorexigenic a-MSH signaling pathway, and that this effect is mediated by direct action on local Y4 receptors within
the ARC, highlighting a potential novel avenue for the treatment of obesity.
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Introduction
The worldwide prevalence of obesity and type 2-diabetes are
increasing at an alarming rate. Although reductions of only 5–10%
body weight can significantly reduce the risk of obesity-associated
co-morbidities such as type 2 diabetes [1], the majority of people
who lose excess weight by lifestyle interventions regain the weight
they lost within two years [2]. There is an urgent need for novel
strategies to boost the effectiveness of lifestyle interventions for
weight loss.
Recent interest has surged in the possible pharmaceutical use
of ligands for Y receptors as anti-obesity agents. Y receptors (Y1,
Y2, Y4, Y5 and y6) are a family of G-protein-coupled receptors
with three endogenous ligands: the orexigenic neuropeptide Y
( N P Y )a sw e l la st h eg u t - d e r i v e ds a t i e t yh o r m o n e sp e p t i d eY Y
(PYY) and pancreatic polypeptide (PP). Much interest has
focused on pharmacological antagonism of Y1 and Y5 receptors,
due to their designation as ‘feeding receptors’ [3]. However,
whereas Y1 receptor deficient mice exhibit reduced fasting-
induced food intake, they develop late-onset obesity [4,5].
Paradoxically, Y5 receptor knockout mice are hyperphagic and
are not protected against leptin-deficiency-induced obesity [6],
and a Y5 receptor antagonist failed to provide clinically
meaningful effects in human weight loss trials [7]. Y2 receptors
have also been flagged as potential targets for novel anti-obesity
agents, since PYY3-36, an endogenous Y2-preferring ligand,
reduces food intake in lean [8] and obese [9] humans and
reduces body weight and adiposity after chronic administration
to obese rodents [10,11]. Like other gut-derived satiety
hormones such as glucagon-like peptide-1, however, PYY3-36
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8488has been shown to induce nausea or conditioned taste aversion
at doses that reduce food intake [12,13,14]. This could limit the
effectiveness of PYY3-36 or Y2-preferring agonists as treatments
for obesity.
PP, like PYY and NPY, can act on all Y receptors, but PP has
the highest affinity for Y4 receptors [15]. PP-like compounds are
under development as potential anti-obesity agents, in light of the
fact that short-term peripheral PP administration to lean people
[16,17] or to obese people with Prader Willi Syndrome [18,19,20]
significantly reduces appetite and food intake. PP dose-depen-
dently reduces food intake in freely fed and fasted mice, and this
effect is entirely mediated through Y4 receptors since the effect
was completely abolished in Y4 receptor knockout mice [21]. Low
circulating levels of PP have been observed in obese people and in
people with obesity caused by Prader Willi Syndrome as well as in
congenitally obese rodents [19,22,23,24]. Animal studies suggest
that long-term administration of PP would lead to significant
benefits in the treatment of obesity. Indeed, PP transgenic mice
exhibit reductions in food intake, body weight and fat mass, as well
as reduced gastric emptying [25], and long-term peripheral
administration of PP to genetically obese ob/ob mice significantly
reduces food intake and body weight while reducing gastric
emptying and increasing energy expenditure [26]. Importantly
from a clinical perspective, PP does not seem to induce nausea
[16,17]. This may be related to the fact that Y4 receptors are only
expressed at significant levels in the hypothalamus and the brain
stem [27,28], which may allow for more specific effects with fewer
side effects if Y4 receptors were targeted with anti-obesity
treatments.
Y4 agonism with PP is thought to mediate effects on appetite
and energy balance by actions within the brainstem, resulting in
modulation of digestive processes such as gastric secretion, motility
and emptying by modulating vagal cholinergic pathways [25,29].
In keeping with vagally-mediated alterations in gut function, the
ability of peripheral PP administration to decrease both efferent
activity of the gastric vagal nerve as well as food intake was
abolished in vagotomized rodents [26].
While Y4 agonism with PP in the brainstem is implicated in
reducing food intake via indirect effects on gastrointestinal
function, the hypothalamus also appears to be involved.
Repeated administration of PP to mice over 24 hours
significantly reduced mRNA expression of the orexigenic
neuropeptide Y (NPY) and orexin in the hypothalamus [26].
However, it is not known in which hypothalamic nuclei and
via which hypothalamic pathways Y4 agonism may reduce
food intake. Y4 receptors are expressed in the arcuate nucleus
of the hypothalamus (ARC) [27,28], which is accessible to
circulating factors such as PP [30]. The aim of this study was
to determine the pathways subsequent to Y4 receptor
activation via which PP reduces food intake, with particular
focus on the early responses to Y4 agonism within the ARC.
This was achieved with c-Fos immunostaining to determine
which regions of the brain are activated at 30 minutes after PP
injection, as well as double immunohistochemistry to deter-
mine which neurons are activated by PP, and in situ
hybridization to determine acute effects of PP on expression
of key hypothalamic regulators of energy homeostasis.
Additionally, we used conditional deletion of Y4 receptors
within the ARC to determine the specific involvement of these
receptors in processes that regulate food intake in response to
PP. Finally, we used germline knockout of molecules activated
by Y4 agonism, in order to demonstrate the pathways through
which Y4 receptor agonism induces its effects on the ARC and
subsequently on food intake.
Materials and Methods
Ethics Statement and Animals
All research and animal care procedures were approved by the
Garvan Institute / St Vincent’s Hospital Animal Ethics Commit-
tee and the study was conducted in accordance with the Garvan
Institute’s guidelines for animal husbandry. Mice were housed
under conditions of controlled temperature (22uC) and illumina-
tion (12-hour light cycle, lights on at 07:00 hours) with ad libitum
access to water and normal chow (6% kilojoules from fat, 21%
kilojoules from protein, 71% kilojoules from carbohydrate, 2.6
kilocalories/g, Gordon’s Specialty Stock Feeds, Yanderra, NSW,
Australia) unless otherwise stated. Adult male wild type and Y4
receptor knockout (Y4
2/2) or conditional Y4 receptor knockout
(Y4
lox/lox) mice on a mixed C57/Bl6 - 129SvJ background,
generated as described previously [31], as well as adult male
melanocortin 4 receptor knockout (MC4R
2/2) mice on the same
mixed background (The Jackson Laboratory, Bar Harbour, Maine
USA) were used. The average body weight of wild type, Y4
2/2 or
Y4
lox/lox mice used in these studies was 25.761.3 g with no
significant difference among groups, and the average body weight
of MC4R
2/2 mice was 30.961.2 g. Unless otherwise stated, all
mice were fasted for 24 hours prior to administration of PP in
order to maximize effects of PP on food intake and other
parameters, as fasting has been shown to enhance the ability of
other gut-derived satiety hormones to illicit significant hypophagic
effects [32].
Hypothalamus-Specific Y4 Receptor Deletion
Hypothalamus-specific Y4 receptor deletion was induced as
previously described [33]. In brief, conditional Y4
lox/lox mice were
anesthetized with ketamine and xylazine at 100 mg/kg and
20 mg/kg (Parke Davis-Pfizer, Sydney, Australia and Bayer AG,
Leverkusen, Germany, respectively), and unilaterally injected with
a recombinant Cre-recombinase-expressing adeno-associated viral
vector (AAV-Cre) using a stereotaxic frame (Kopf Instruments,
Tujunga, CA, USA). The non-injected side of the hypothalamus
was used as an internal control. As an additional control,
additional Y4
lox/lox mice were unilaterally injected with an empty
adeno-associated viral vector (AAV-empty). Brain injection co-
ordinates relative to bregma were posterior 1.94 mm, lateral
60.3 mm, ventral 5.75 mm, corresponding to the ARC [34]. Cre-
recombinase- or empty-expressing virus (10
211 Pfu in 1.5 ml) was
injected unilaterally over 5 minutes using a 1.5 ml needle
connected to a Hamilton Syringe (Hamilton Company, Reno,
Nevada, USA). Mice were housed individually for the ensuring 28
days and allowed continuous ad libitum access to food and water (no
fasting) prior to i.p. PP injection and subsequent determination of
c-Fos-like immunoreactivity and POMC mRNA expression levels
in the ARC as described below. In order to confirm Y4 gene
deletion in conditional knockout mice, genomic DNA was isolated
from hypothalamic blocks from AAV-Cre injected and non-
injected control mice as well as from the cerebellum of the same
mice by standard technology. PCR was performed with primers
(Primer A 59-GCATCTGTACTGAGTGGC-39 and Primer B 59-
ATCCTTCCTGCCTCTATG-39) that only produce a product of
290 base pairs from DNA in which the Y4-receptor gene had been
deleted. PCR conditions were 5 minutes denaturation at 95uC
followed by 35 cycles of 1 minute at 95uC, 1 minute at 55uC and
40 seconds at 72uC.
Determination of PP-Induced Changes in Food Intake
Wild type, Y4
2/2 or MC4R
2/2 animals were single housed
with a paper towel on the bottom of the cage replacing fibrous
Y4, POMC, MC4 and PP in Satiety
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from the cage hopper 24 hours prior to experimentation. Animals
either received PP (Bachem AG, Bubendorf, Switzerland) at 200,
300 or 500 mg/kg or saline vehicle (0.9% sodium chloride, 10 ml/
kg) via intraperitoneal injection between 09:00–10:00 hours.
Animals were given free access to chow diet directly following
injection. Food intake was measured at 4, 8 and 24 hours
following PP or vehicle administration and re-feeding. Food
consumption was measured as the weight of food taken from the
hopper minus the weight of food spilled on the cage floor. Data are
presented as cumulative food intake, calculated as the sum of food
consumed during the 24 hours directly following re-feeding. As the
lowest dose of PP (200 mg/kg) and this dosing paradigm produced
a significant reduction in food intake in wild type mice, this dose
was used for all studies unless otherwise stated.
Immunohistochemistry for Determination of PP-Induced
Changes in Brain c-Fos or P-Erk1/2 Expression
Wild type and Y4
2/2 or unilaterally AAV-Cre-injected Y4
lox/lox
conditional knockout mice were injected with PP (i.p. 200 mg/kg
body weight) or saline vehicle in a volume of 10 ml/kg between
10:00 to 12:00 hours. Mice used for determination of P-Erk1/2
immunoreactivity were allowed continuous ad libitum access to food
prior to PP injection. At 30 or 90 minutes after i.p. injection for c-
Fos immunoreactivity, or at 30 minutes after i.p. injection for P-
Erk1/2 immunoreactivity, mice were deeply anaesthetized with
ketamine / xylazine (100 mg/kg and 20 mg/kg from Parke Davis-
Pfizer, Sydney, Australia and Bayer AG, Leverkusen, Germany,
respectively) and perfused via the left ventricle and right carotid
artery with 25 ml phosphate buffered saline following by ice-cold
4% paraformaldehyde made in phosphate buffered saline. This
30 minute time point was chosen because our previous experience
with another molecule that regulates food intake, macrophage
inhibitory cytokine-1 (MIC-1) [35], revealed that this 30 minute
time point is important for determining specific neuronsin the brain
that are activated after peripheral administration of MIC-1.
However, to more comprehensively investigate the activation of c-
Fos in response to i.p. PP administration, we also looked at a 90
minute time point. Brains were immediately removed and placed in
4% paraformaldehyde for 30 minutes and then in phosphate
buffered saline containing 30% sucrose in which they remained
overnight.Coronalslicesof30 mmthicknessweremounted onslides
(Menzel-Glaser, Braunschweig, Germany) and washed in 1% H2O2
in 50% alcohol for 20 minutes to abolish endogenous peroxidase
activity. Sections were incubated overnight at room temperature
with the primary antibody, rabbit-anti-mouse c-Fos (Santa Cruz
Biotechnology Inc, Santa Cruz, CA, USA) or rabbit-anti-mouse P-
Erk1/2 (Cell Signaling Technology Inc, Danvers, MA, USA)
diluted at 1:4000 in phosphate buffered saline containing 0.1%
Triton x-100. After three 10-minute washes in PBS-Triton, sections
wereincubatedfor3 hourswith the biotinylatedsecondaryantibody
(Sigma-Aldrich, St Louis, MO, USA), diluted 1:250 in phosphate
buffered saline. Sections were washed three times for 10 minutes
each in phosphate buffered saline and then incubated with Avidin-
Biotin-Peroxidase VectastainH (Vector Laboratories, Burlingame,
CA, USA) for 30 minutes at room temperature. Sections were
rinsed in phosphate buffered saline and treated with diaminobenzi-
dine(Dako,Carpinteria,CA,USA)for5minutes.Slideswererinsed
in water and dehydrated through to xylene before cover slipping.
Sections were visualized for c-Fos-like immunoreactivity or P-Erk1/
2 immunoreactivity using a Zeiss Axiophot microscope equipped
with the ProgRes digital camera (Carl Zeiss Imaging Solutions
GmbH,Munich,Germany).Twelvesectionsfrom each mousewere
counted by investigators blinded of the genotype and treatment of
the samples for darkly stained nuclei representing c-Fos-like or P-
Erk1/2 immunoreactivity within the brain nuclei of interest, which
were defined according to the mouse brain atlas [34]. Data are
represented as the average number of c-fos-like or P-Erk1/2
immunoreactive neurons per section in each nucleus, averaged over
4–6 mice per group.
Double Labeling Studies for c-Fos Immunohistochemistry
with TH, a-MSH or GAD65
Double labeling studies were performed to determine the
chemical identity of neurons activated by PP injection, as indicated
by c-Fos immunoreactivity. Six male wild type mice were used for
each double labeling study. Twenty-four hour fasted wild type
mice were injected with either PP (i.p. 200 mg/kg) or saline in a
volume of 10 ml/kg between 10:00 to 12:00 hours. At 30 minutes
after i.p. injection, mice were anesthetized and perfused and brains
post-fixed as described above. Brains were frozen in mounting
media (Tissue-Tek, ProScitech, Thuringowa, QLD, Australia) and
35 mm coronal sections were cut on a cryostat at 210uC. Brain
sections were washed in 1% H2O2 in 50% alcohol for 20 minutes
to abolish endogenous peroxidase activity.
The primary antibodies, rabbit-anti-mouse c-Fos (Santa Cruz
Biotechnology Inc, Santa Cruz, CA, USA), sheep anti-mouse TH
(Santa Cruz Biotechnology Inc) or sheep anti-mouse a-MSH
(AB5087, Chemicon, Temecula, CA, USA), were diluted at
1:4000, 1:3000 or 1:5000 respectively in phosphate buffered saline
containing 0.1% Triton x-100 and then incubated with slide-
mounted sections at room temperature overnight. After washing
three times for 10 minutes each in phosphate-buffered saline-
triton, sections were incubated for 3 hours at room temperature
with goat anti-rabbit or donkey anti-sheep secondary antibodies
conjugated to fluorophores (Molecular ProbesH Alexa FluorH 594
and Alexa FluorH 488 from Invitrogen, Carlsbad, CA, USA),
diluted 1:250 in phosphate buffered saline. Sections were washed
three times in phosphate buffered saline for 10 minutes each and
fluorophore signals (red for c-Fos and green for TH or a-MSH)
were visualized under a Zeiss Axioplan (Oberkochen, Germany)
light microscope.
For c-Fos and GAD65 double immunostaining, primary
antibodies, goat-anti-mouse c-Fos (Santa Cruz Biotechnology
Inc, Santa Cruz, CA, USA) and rabbit-anti-mouse GAD65
(AB5082, Chemicon, Temecula, CA, USA) were diluted at
1:4000 and 1:2000 respectively in phosphate buffered saline
containing 0.1% Triton x-100 and then incubated with slide-
mounted sections at room temperature overnight. After washing
three times for 10 minutes each in phosphate-buffered saline-
triton, sections were incubated for 2 hours at room temperature
with biotinylated anti-goat secondary antibody (Chemicon,
Temecula, CA, USA) diluted 1:250 in phosphate buffered saline.
Sections were then washed three times in phosphate buffered
saline for 10 minutes each and incubated for 30 minutes at room
temperature with avidin-biotin-peroxidase (Sigma-Aldrich, St
Louis, MO, USA). Sections were washed in phosphate buffered
saline and treated with 0.05% diaminobenzidine tetrahydrochlor-
ide (Sigma-Aldrich, St Louis, MO, USA) and 0.007% hydrogen
peroxide in the presence for 0.04% nickel ammonium sulphate to
stain for c-Fos immunoreactivity. Section were then washed in
phosphate buffered saline and incubated for 2 hours at room
temperature with the biotinylated anti-rabbit secondary antibody
(Sigma-Aldrich, St Louis, MO, USA) diluted 1:250 in phosphate
buffered saline. Sections were then washed three times for 10
minutes each in phosphate buffered saline and incubated for 30
minutes at room temperature with Avidin-Biotin-Peroxidase
VectastainH (Vector Laboratories, Burlingame, CA, USA).
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diaminobenzidine (Dako, Carpinteria, CA, USA) to detect
GAD65 immunoreactivity. Slides were rinsed in water and
dehydrated through to xylene before cover slipping.
To quantitate co-localization of c-Fos immunoreactivity with
TH, a-MSH and GAD65 in the NTS, AP and ARC, the number
of double-labeled neurons in each region was divided by the
number of c-Fos-positive and the number of TH-, a-MSH-, or
GAD65-positive neurons in each site. Stained neurons were
counted in 3–4 distinct sections from both hemispheres.
In Situ Hybridization for Quantification of POMC, GAD65
and NPY mRNA Expression
Ten 24 hour-fasted wild type mice and 8 ad libitum-fed
unilaterally AAV-Cre-injected Y4
lox/lox conditional knockout
mice were injected with either PP (i.p. 200 mg/kg) or saline in a
volume of 10 ml/kg between 10:00 to 12:00 hours. All mice were
killed by cervical dislocation and decapitation 30 minutes after
injection, and brains were immediately removed and frozen.
Coronal sections, 20 mm thick, of fresh frozen brains were cut and
thaw-mounted on charged slides and stored at 220uC until use.
For radioactive in situ hybridisation, DNA oligonucleotides
complementary to mouse POMC (59-TGGCTGCTCTCCAGG-
CACCAGC-TCCACACATCTATGGAGG-39), GAD65 (59GC-
GTCCACAC TGCAAGGCCTTGTCTCCTGTGTCATAGG-
ACAGGTC-39)o rN P Y( 5 9-GAGGGTCAGTCCA CACAGC-
CCCATTCGCTTGTTACCTAGCAT-39) were labeled with
[
35S] thio-dATP (Amersham Biosciences, Little Chalfont, Buck-
inghamshire, UK) using terminal deoxynucleotidyltransferase
(Roche, Mannheim, Germany). The expression levels of POMC,
GAD65 and NPY mRNA were evaluated by measuring silver
grain densities over individual neurons from photo-emulsion-
dipped sections, as described previously [33].
Statistical Analyses
All data were assessed by factorial ANOVA followed by Fisher’s
or Contrasts post-hoc tests, using StatView version 4.5 or Super-
ANOVA (Abacus Concepts Inc, CA, USA). For all statistical
analyses, P,0.05 was accepted as being statistically significant.
Results
Y4 Agonism with PP Activates Neurons in Key Brainstem
and Hypothalamic Nuclei Implicated in Energy Balance
To determine which regions of the brain might be involved in
mediating the PP-induced reduction in food intake and to identify
the neuronal populations concerned, we tracked changes in
expression of the neuronal activation marker, c-Fos, in response to
i.p. PP injection. Significant increases in the number of c-Fos
immunoreactive neurons were detected in the nucleus tractus
solitarius (NTS) and the area postrema (AP) of the brainstem as
well as in the ARC as early as 30 minutes after PP injection
(Table 1, Figure 1). These c-Fos responses to PP were transient,
because at 90 minutes post injection the levels of c-Fos positive
neurons in the NTS, AP and ARC were no longer different from
baseline levels (Table 1). However, other regions of the
hypothalamus showed increased c-Fos labeling also at 90 minutes
after PP injection, namely the paraventricular nucleus of the
hypothalamus (PVN), the dorsomedial part of the ventromedial
nucleus of the hypothalamus (VMHDM) and the lateral
hypothalamic area (LHA, Table 1). Noteworthy is the fact that
the level of c-Fos immunoreactivity in the PVN and LHA was
significantly greater at 90 minutes than at 30 minutes after PP
injection, suggesting that the heightened response in these nuclei at
90 minutes may include secondary responses to initial activation of
other neurons in brain regions such as the brainstem or ARC.
Saline injected control mice did not show any difference in c-Fos
immunoreactivity at 90 minutes compared to 30 minutes in any
brain area (data not shown). Consistent with a specific role of Y4
receptors in PP-induced neuronal activation, these increases in c-
Fos immunoreactivity were not observed in the brains of Y4
receptor knockout mice after PP injection (Table 1, Figure 1). As
further functional evidence that PP activates intracellular processes
within the ARC, immunoreactivity for phosphorylated extracel-
lular signal-regulated kinases 1 and 2 (P-Erk1/2), a marker of
activation of intracellular signaling cascades affected by G-protein-
coupled receptors, was strongly increased at 30 minutes after i.p.
PP injection (Figure 2A+B).
Chemical Identity of Neurons Activated by Y4 Agonism
with PP
To determine the chemical identity of neurons activated by i.p.
PP injection and therefore gain insight into the mechanisms by
which Y4 agonism with PP reduces food intake, we combined
immunostaining for c-Fos with immunostaining for known key
regulators of energy balance. In the NTS and AP of the brainstem,
neurons containing c-Fos immunostaining at 30 minutes after PP
injection also showed immunostaining for tyrosine hydroxylase
(TH), the rate-limiting enzyme in the synthesis of catecholamines
(Figure 2C–F). In fact, 52.166.1 and 46.465.0% of c-Fos positive
neurons in the NTS and AP respectively were positive for TH
immunoreactivity, and 85.264.5 and 66.1611.5% of TH positive
neurons in the NTS and AP respectively were positive for c-Fos
immunoreactivity after PP injection (data are means 6 SEM of 3–
4 sections). These findings suggest that PP may induce part of its
effects on food intake via catecholaminergic transmission from the
NTS and AP to the hypothalamus, pathways known to exist
between the hindbrain and hypothalamus [36]. Additionally,
brainstem mechanisms have been shown to mediate effects of PP
on gastrointestinal functions, which can in turn influence food
intake indirectly [25,26,29]. In order to elucidate pathways by
which PP may reduce food intake via direct effects on
hypothalamic feeding centers, we investigated changes in the
ARC in response to PP injection in further detail.
Table 1. Number of c-Fos-like immunoreactive neurons in
the brainstem and hypothalamus of wild type and Y4 receptor
knockout (Y4
2/2) mice at 30 or 90 minutes after i.p. injection
of saline or pancreatic polypeptide (PP).
Regions
Wild type Saline
(30 min)
Wild type PP
(30 min)
Wild type PP
(90 min)
Y4
2/2 PP
(30 min)
NTS 10622 3 66*
# 14638 62
AP 3612 6 65*
# 5623 61
ARC 9623 8 65*
# 13638 61
PVN 15624 2 66*
# 60616* 1463
VMHDM 20627 1 65* 6766* 1963
LHA 19644 3 68*
# 78629* 1763
Data are means 6 SEM of 4–6 mice per groups.* P,0.05 versus saline-injected
wild type mice; # P,0.05 versus PP-injected wild type mice (90 minutes). NTS:
nucleus tractus solitarus; AP: area postrema; ARC: arcuate nucleus of the
hypothalamus; PVN: paraventricular nucleus of the hypothalamus; VMHDM:
dorsomedial part of the ventromedial nucleus of the hypothalamus; LHA: lateral
hypothalamic area.
doi:10.1371/journal.pone.0008488.t001
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c-Fos immunoreactivity at 30 minutes after i.p. injection) showed
immunostaining for alpha melanocyte stimulating hormone (a-
MSH), the anorexigenic product of the proopiomelanocortin
(POMC) gene, as well as glutamic acid decarboxylase 65 (GAD65),
a key enzyme in the synthesis of the neurotransmitter gamma-
aminobutyric acid (GABA) (Figure 3). Indeed, 55.061.5 and
35.063.1% of ARC neurons that were positive for c-Fos after PP
injection were also positive for a-MSH and GAD54, respectively.
Conversely, 84.461.1 and 86.362.1% of a-MSH- and GAD54-
positive neurons in the ARC were also positive for c-Fos
immunoreactivity after PP injection (data are means 6 SEM of
3–4 sections). These findings suggest a link between PP-induced
hypophagia with a-MSH- and GABA-ergic signaling.
Y4 Agonism with PP Stimulates POMC and Inhibits
GAD65 Expression with No effect on NPY Expression in
the ARC
Our finding that PP activates c-Fos immunoreactivity in a-
MSH-immunoreactive neurons, combined with the known role of
ARC a-MSH to inhibit food intake and body weight gain [37], led
us to hypothesize that the melanocortin system may be a key
mediator of the anorectic effects of PP.We therefore investigated
the expression of POMC in response to i.p. PP injection. Indeed,
mice injected with PP showed a significant increase in ARC
POMC mRNA levels relative to saline-injected controls at 30
minutes after injection (Table 2, Figure 4A+C). As ARC POMC
neurons are negatively regulated by GABA-ergic neurons
[38,39,40,41], we also investigated the effect of PP on GAD65
expression. PP injection significantly reduced ARC GAD65
mRNA expression within 30 minutes compared to expression
levels in saline-injected mice (Figure 4B+D, Table 2). Contrarily,
PP had no effect on ARC NPY mRNA levels (Table 2), suggesting
that PP-induced hypophagia is not mediated via changes in NPY
expression. This is consistent with our observation that PP induced
c-Fos immunoreactivity in cells in the lateral aspect of the ARC
that preferentially express POMC but little NPY, whereas the
dorsal aspect of the ARC, known to express NPY [42], showed
little PP-induced c-Fos activation (Figure 1C+F).
Direct Role of ARC Y4 Receptors in PP-Induced c-Fos
Activation and Induction of POMC Expression
In order to determine the role of Y4 receptors specifically in the
ARC in mediating PP-induced effects, we used conditional Y4
receptor knockout (Y4
lox/lox) mice which had been unilaterally
injected into the ARC with a Cre-recombinase-expressing adeno-
associated viral vector (AAV-Cre) in order to induce specific local
Y4 receptor deletion, and then investigated c-Fos immunoreac-
tivity and POMC mRNA expression in the ARC at 30 minutes
after i.p. PP injection. Unilateral injection of AAV-Cre was chosen
because by injecting only one side of the hypothalamus, one can
directly use the contra-lateral side as an internal control, thereby
avoiding inter-animal variations and demonstrating the direct
consequences of lack of Y4 receptors on neuronal responses and
gene expression. As an additional control, different animals were
unilaterally injected with an empty adeno-associated viral vector
Figure 1. Pancreatic polypeptide (PP) injection induces a Y4 receptor-dependent increase in c-Fos immunoreactivity in the
brainstem and hypothalamus. (A,B and C) Photomicrograph of brains from wild type (WT) mice showing c-Fos immunoreactivity at 30 minutes
after i.p. injection of saline. (D, E and F) Brains from wild type mice showing c-Fos immunoreactivity at 30 minutes after i.p. injection of PP. (G, H and I)
Brains from Y4 receptor knockout mice (Y4
2/2) showing c-Fos immunoreactivity at 30 minutes after i.p. injection of PP. Scale bar for all panels =
40 mm. NTS, nucleus tractus solitarus; AP, area postrema; ARC, arcuate nucleus of the hypothalamus; 3V, third cerebral ventricle.
doi:10.1371/journal.pone.0008488.g001
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confirmed by PCR of genomic DNA isolated from the
hypothalamus of AAV-Cre-injected or non-injected mice using a
primer set that only produces a product from DNA in which gene
deletion has occurred (Figure 5A+B). As an internal negative
control, DNA isolated from the cerebellum of the same AAV-Cre
injected conditional knockout mice was used.
Results from this conditional knockout experiment show that in
the non-AAV-Cre-injected contra-lateral side of the ARC, c-Fos
immunoreactivity (Figure 5C) and POMC mRNA expression
(Figure 5D) were increased after i.p. PP injection, whereas the
AAV-Cre-injected side of the ARC, in which Y4 receptors had
been deleted, showed markedly reduced c-Fos and POMC
staining (1962 versus 2763 c-Fos positive neurons, and
81.461.2 versus 10065.7 percent of POMC mRNA expression
levels in the deleted versus non-deleted side of the ARC, data are
means 6 SEM of 8 mice, P,0.05). In mice that had been
unilaterally injected with control virus (AAV-empty), no such
reduction in POMC mRNA expression was seen in the injected
versus the non-injected side of the hypothalamus after i.p. PP
injection (Figure 5E). This result proves that Y4 receptors within
the ARC are important mediators of local PP-induced c-Fos
activation, and that PP action via Y4 signaling in the ARC
controls POMC mRNA expression.
Y4 Agonism with PP Reduces Food Intake via a-MSH
Mediated Signaling
To determine whether PP-induced c-Fos activation in a-MSH-
immunoreactive neurons and up-regulation of POMC mRNA
levels in the ARC in response to PP is functionally implicated in
the anorectic effect of PP, we investigated PP-induced food intake
in mice deficient in the melanocortin 4 receptor (MC4R), the
receptor via which a-MSH induces its anorexigenic effects [43].
Interestingly, whereas i.p. injection of PP into wild type mice
induced a significant reduction in food intake compared to saline-
injected controls, no such effect of any of the three doses of PP
used was seen after i.p. injection into MC4R knockout mice
(Figure 6), demonstrating that PP mediates its anorectic effect via
modulating MC4R pathways.
Discussion
This study demonstrates that reduction in food intake induced
by Y4 receptor agonism with PP is mediated by activation of the
Figure 2. Immunoreactivity for phosphorylated extracellular signal-regulated kinases 1 and 2 (P-Erk1/2) in the hypothalamus and
co-expression of c-Fos and tyrosine hydroxylase (TH) immunoreactivity in the brainstem after PP injection. (A) Brightfield micrograph
showing P-Erk1/2 immunoreactivity in the arcuate nucleus of the hypothalamus (ARC) at 30 minutes after i.p. injection of PP in wild type mice. Scale
bar=200 mm. (B) Higher magnification of the boxed area from A. Scale bar =5 mm. (C, E) Fluorescence micrographs of the nucleus tractus solitarius
(NTS) and area postrema (AP) respectively, 30 minutes after i.p. injection of PP. Scale bar =40 mm. (D, F) Higher magnifications of the NTS and AP,
respectively, from the boxed areas in C and E. Scale bar =25 mm. White arrows indicate neurons positive for c-Fos immunoreactivity only (red
fluorescence); white arrowheads indicate neurons positive for TH immunoreactivity only (green fluorescence); blue arrows indicate neurons double-
labeled for c-Fos and TH. 4V, fourth cerebral ventricle; cc, central canal.
doi:10.1371/journal.pone.0008488.g002
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g i ai sa b s e n ti nMC4R
2/2 mice. Moreover, the ability of Y4 receptor
agonism with PP to activate the ARC POMC / a-MSH system is
mediated by Y4 receptors within the ARC, since conditional knockout
of Y4 receptors specifically in this area abolishes PP-induced activation
of c-Fos and induction of POMC expression in the ARC.
Furthermore, double labeling revealed that the ARC neurons
activated by peripheral PP contained immunoreactivity for a-MSH
as well as GAD65, a key enzyme in the synthesis of GABA. Besides
enhancing ARC mRNA expression of the precursor for a-MSH,
Figure 3. Pancreatic polypeptide (PP) injection induces c-Fos immunoreactivity in neurons positive for alpha melanocyte
stimulating hormone (a-MSH) and glutamic acid decarboxylase 65 (GAD65) in the arcuate nucleus of the hypothalamus (ARC). (A) c-
Fos immunoreactivity, (B) a-MSH immunoreactivity, and (C) overlay of c-Fos and a-MSH immunoreactivity in neurons as indicated by white arrows at
30 minutes after i.p. injection of PP. Sale bar for A–C =25 mm. (D) Brightfield micrograph showing c-Fos and GAD65 immunoreactivity at 30 minutes
after i.p. injection of PP. Scale bar =200 mm. (E) Higher magnification of the boxed area from D. Black arrows indicate neurons positive for c-Fos
immunoreactivity only. These neurons are darkly stained. Black arrowheads indicate neurons positive for GAD65 immunoreactivity only. These
neurons are lightly stained. Red arrows indicate neurons double-labeled for c-Fos and GAD65. The double staining on these neurons makes these
neurons appear larger than the neurons positive only for c-Fos or CAG65 immunoreactvity. Scale bar =5 mm. 3V, third cerebral ventricle.
doi:10.1371/journal.pone.0008488.g003
Table 2. Expression of proopiomelanocortin (POMC),
glutamic acid decarboxylase 65 (GAD65) and neuropeptide Y
(NPY) mRNA in the arcuate nucleus of the hypothalamus at 30
minutes after i.p. injection of saline or pancreatic polypeptide
(PP).
mRNA saline PP
POMC 100612.4 268612.0***
GAD65 100617.3 6069.2**
NPY 100610.6 10364.4
Data are means 6 standard error of 5 wild type mice per group, with neuron
labeling intensity expressed as a percentage of saline-injected controls.
**, P,0.01; ***P,0.001 versus saline-injected controls.
doi:10.1371/journal.pone.0008488.t002
Figure 4. Effects of pancreatic polypeptide (PP) on the
expression of proopiomelanocortin (POMC) and GAD65 mRNA
in the arcuate nucleus of the hypothalamus (ARC). Emulsion-
dipped autoradiographs showing POMC mRNA at 30 minutes after i.p.
injection of (A) saline or (C) PP, orGAD65 mRNA at 30 minutes after i.p.
injection of (B) saline or (D) PP. Scale bar for all panels =25 mm. 3V,
third cerebral ventricle.
doi:10.1371/journal.pone.0008488.g004
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together, these findings suggest that peripheral PP may act on Y4
receptors within the ARC to activate a-MSH- and GABA-ergic
neurons and thereby stimulate POMC and inhibit GAD65 mRNA
expression, ultimately increasing a-MSH action on MC4Rs and
reducing food intake.
While it is clear that hypothalamic Y4 receptors (i.e. in the
ARC) are required for PP-induced neuronal activation and
stimulation of POMC mRNA expression, this effect could be
mediated by direct and / or indirect effects on POMC neurons.
Y4 receptors are known to be expressed in the ARC [28], but it is
not known on which neurons (e.g. POMC or GABA-ergic
neurons) they are expressed. Our data support the possibility that
PP influences POMC neurons via indirect action on GABA-ergic
neurons. Indeed, PP increased c-Fos immunoreactivity in GAD65-
expressing neurons, but at the same time significantly reduced
GAD65 mRNA expression. Whereas PP-induced activation of c-
Fos immunoreactivity in GAD65-expressing neurons is most likely
via activation of the mitogen-activated protein (MAP) kinase
pathway by the bc-subunits of the G-protein that is coupled to Y4
receptors, inhibition of GAD65 mRNA expression in response to
PP probably involves Y4 receptor-initiated inhibition of cAMP
production via a subunits of the Gi/o protein coupled to Y4
[44,45], thereby reducing GABAergic neurotransmission onto
POMC neurons [46]. GABA synthesized in the ARC is released
within the ARC as well as in other brain regions to modulate
neuronal circuits that control physiological responses such as food
intake. For instance, GABA-ergic nerve terminals synapse with
POMC-containing neurons in the ARC [38,39], and GABA
reduces mRNA expression of POMC and inhibits the release of a-
MSH in the ARC [40,41]. Albeit co-localization of Y4 receptors
on ARC GABA-ergic neurons remains to be demonstrated, these
findings raise the possibility that the action of PP on Y4 receptors
on GABA-ergic neurons in the ARC could contribute to PP-
induced hypophagia via inhibition of GABA-ergic inputs to
POMC neurons, with a subsequent increase in POMC expression
and a-MSH transmission.
Figure 5. Conditional deletion of Y4 receptors in the arcuate nucleus of the hypothalamus (ARC) alters pancreatic polypeptide (PP)-
induced c-Fos immunoreactivity and POMC mRNA expression. (A) Schematic representation of primer positions used for PCR verification of
Y4 receptor gene knockout.The un-deleted gene is 3.4 kilobases, and after Cre-mediated Y4 receptor gene deletion a PCR product of 290 base pairs is
produced. (B) Confirmation of Y4 receptor deletion (indicated by production of the 290 base pair PCR product) from DNA isolated from the
hypothalamus (Hypo) but not from the cerebellum (Cer) of Y4 receptor conditional knockout (Y4F) mice injected with AAV-Cre recombinase into the
ARC, or from mice not injected with AAV-Cre(Y4F Hypo). (C) Photomicrograph showing c-Fos immunoreactivity and (D+E) emulsion-dipped
autoradiograph of POMC mRNA expression in the brain of a conditional Y4 receptor knockout mouse, 30 minutes after i.p. injection of PP. Mice
received unilateral injection of (D) AAV-Cre or (E) AAV-empty 28 days prior to PP injection in order to induce local deletion of Y4 receptors by virally-
delivered Cre-recombinase, the contra-lateral side (at left in C, D and E) was used as control. Scale bar =100 mm in C and 25 mm in D and E. 3V, third
cerebral ventricle.
doi:10.1371/journal.pone.0008488.g005
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and GAD65 expression – ARC NPY mRNA expression was not
altered after PP injection. This is in keeping with our observation
that PP injection induced c-Fos activity in the lateral (not dorsal)
aspect of the ARC, a region known to express POMC but not
NPY [42]. Previously it was shown that four i.p. injections of PP
over 24 hours (a total dose more than double the single acute
dose used presently) significantly reduced NPY mRNA expres-
sion in the whole hypothalamus as determined by real-time PCR
[26]. Our current data suggest that any effect of PP on
hypothalamic NPY expression is not a primary effect of PP
action. In contrast, this work reveals a key role of the
melanocortin system in mediating satiety in response to PP.
Interestingly, not all gut satiety hormones act via the melano-
cortin system. For instance, whereas i.p. PYY3-36 injection in
mice modestly activates POMC neurons [8,47] and significantly
increases POMC mRNA expression in the ARC [32], the
hypophagic effect of PYY3-36 is just as apparent in MC4R
2/2 as
in wild type mice [47]. Therefore, other pathways besides the
melanocortin system – such as those that induce nausea or food
aversion [12] – must be important in mediating PYY3-36-
induced satiety. The specific involvement of the melanocortin
system in PP-induced satiety may explain why PP has been
shown to reduce food intake without any reports of concomitant
nausea [16,17]. Although this work focusses on the hypotha-
lamic melanocortin system, potential influences of the brain
stem POMC system cannot be ruled out as contributing to PP-
induced reductions in food intake.
In addition to the brainstem (NTS and AP) and ARC, our data
show that other brain regions are likely involved in mediating
responses to peripheral PP, as indicated by the induction of c-Fos
immunoreactivity in the PVN, VMHDM and the LHA after PP
injection. Activation of these hypothalamic regions may contribute
to the ability of PP to not only reduce food intake but also induce
other physiological effects that could contribute to reduced
adiposity after longer-term administration [25,26], such as
enhancing the activity of sympathetic nerves innervating brown
adipose tissue and stimulating energy expenditure in genetically
obese ob/ob mice [26] and reducing glucose-induced insulin release
after acute administration to obese rodents [20]. For instance, the
PVN is implicated in regulation of sympathetically-mediated
thermogenesis in brown adipose tissue [48], and the VMH is
implicated in regulation of insulin secretion [49]. In light of
previous reports that Y4 agonism with PP mediates effects on
appetite and energy balance by actions within the brainstem to
modulate digestive processes via vagal cholinergic pathways
[25,29], the ability of Y4 receptor agonism with PP to influence
multiple central and peripheral pathways that impact on energy
homeostasis makes Y4 agonists attractive potential anti-obesity
agents.
Taken together, these data show that peripherally-administered
PP reduces food intake via mechanisms requiring Y4 receptor
signalling within the ARC and downstream POMC / a-MSH /
MC4R pathways. These findings not only elucidate critical
biological pathways for feeding behaviour, they also have
important implications for the clinical treatment of obesity. As
Y4 receptors are only expressed in specific regions of the brain
relative to other Y receptors [27,28], an advantage of developing
Y4-specific agonists as novel anti-obesity agents could be a greater
specificity in reducing food intake with fewer side-effects such as
nausea.
Acknowledgments
We thank Dr Jenny Kingham for invaluable veterinary advice, and the staff
of the Garvan Institute Biological Testing Facility. Critical review of this
manuscript by Prof. Gu ¨nther Sperk was greatly appreciated.
Author Contributions
Conceived and designed the experiments: HH AS. Performed the
experiments: SL YCS EY AA LZ LM ADN EJDL. Analyzed the data:
SL AS. Contributed reagents/materials/analysis tools: MJD. Wrote the
paper: SL LZ HH AS.
References
1. (1998) Clinical Guidelines on the Identification, Evaluation, and Treatment of
Overweight and Obesity in Adults–The Evidence Report. National Institutes of
Health. Obes Res 6 Suppl 2: 51S–209S.
2. Wing RR, Hill JO (2001) Successful weight loss maintenance. Annual Review of
Nutrition 21: 323–341.
3. Iyengar S, Li DL, Simmons RM (1999) Characterization of neuropeptide Y-
induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding? Journal
of Pharmacology & Experimental Therapeutics 289: 1031–1040.
4. Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, et al. (1998)
Cardiovascular response, feeding behavior and locomotor activity in mice
lacking the NPY Y1 receptor. Nature Medicine 4: 722–726.
5. Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, et al. (1998) Obesity
and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice.
Proceedings of the National Academy of Sciences of the United States of
America 95: 15659–15664.
6. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD (1998) Role of the Y5
neuropeptide Y receptor in feeding and obesity. Nature Medicine 4: 718–721.
7. Erondu N, Wadden T, Gantz I, Musser B, Nguyen AM, et al. (2007) Effect of
NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-
induced weight loss. Obesity (Silver Spring) 15: 895–905.
8. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, et al. (2002) Gut
hormone PYY3-36 physiologically inhibits food intake. Nature 418: 650–654.
9. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, et al. (2003)
Inhibition of food intake in obese subjects by peptide YY3-36. New England
Journal of Medicine 349: 941–948.
10. Pittner R, Moore C, Bhavsar S, Gedulin B, Smith P, et al. (2004) Effects of
PYY[3-36] in rodent models of diabetes and obesity. International Journal of
Obesity. pp 1–9.
11. Chelikani PK, Haver AC, Reeve JR Jr, Keire DA, Reidelberger RD (2006)
Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food
Figure 6. PP reduces food intake via a melanocortin 4 receptor-
dependent pathway. Twenty four (24) hour food intake (g/day) in
wild type (WT) and melanocortin 4 receptor knockout (MC4R
2/2) mice
after i.p. injection of increasing doses of PP or saline vehicle. Data are
means 6 SEM of 6–8 mice per group. * P,0.05 versus vehicle-injected
wild type mice or the comparison shown by horizontal bars.
doi:10.1371/journal.pone.0008488.g006
Y4, POMC, MC4 and PP in Satiety
PLoS ONE | www.plosone.org 9 December 2009 | Volume 4 | Issue 12 | e8488intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 290:
R298–R305.
12. Halatchev IG, Cone RD (2005) Peripheral administration of PYY3-36 produces
conditioned taste aversion in mice. Cell Metabolism 1: 159–168.
13. Parkinson JR, Chaudhri OB, Kuo YT, Field BC, Herlihy AH, et al. (2009)
Differential patterns of neuronal activation in the brainstem and hypothalamus
following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in
mice detected by manganese-enhanced magnetic resonance imaging (MEMRI).
Neuroimage 44: 1022–1031.
14. Gantz I, Erondu N, Mallick M, Musser B, Krishna R, et al. (2007) Efficacy and
safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin
Endocrinol Metab 92: 1754–1757.
15. Blomqvist AG, Herzog H (1997) Y-receptor subtypes-how many more? Trends
in Neurosciences 20: 294–298.
16. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, et al. (2003)
Pancreatic polypeptide reduces appetite and food intake in humans. J Clin
Endocrinol Metab 88: 3989–3992.
17. Jesudason DR, Monteiro MP, McGowan BM, Neary NM, Park AJ, et al. (2007)
Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr 97:
426–429.
18. Berntson GG, Zipf WB, O’Dorisio TM, Hoffman JA, Chance RE (1993)
Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome.
Peptides 14: 497–503.
19. Glaser B, Zoghlin G, Pienta K, Vinik AI (1988) Pancreatic polypeptide response
to secretin in obesity: effects of glucose intolerance. Hormone and Metabolic
Research 20: 288–292.
20. Gettys TW, Garcia R, Savage K, Whitcomb DC, Kanayama S, et al. (1991)
Insulin-sparing effects of pancreatic polypeptide in congenitally obese rodents.
Pancreas 6: 46–53.
21. Balasubramaniam A, Mullins DE, Lin S, Zhai W, Tao Z, et al. (2006)
Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32–36):
development of an anorectic Y4 receptor selective agonist with picomolar
affinity. J Med Chem 49: 2661–2665.
22. Tomita T, Greeley G Jr, Watt L, Doull V, Chance R (1989) Protein meal-
stimulated pancreatic polypeptide secretion in Prader-Willi syndrome of adults.
Pancreas 4: 395–400.
23. Reinehr T, Enriori PJ, Harz K, Cowley MA, Roth CL (2006) Pancreatic
polypeptide in obese children before and after weight loss. Int J Obes (Lond) 30:
1476–1481.
24. Jia BQ, Taylor IL (1984) Failure of pancreatic polypeptide release in
congenitally obese mice. Gastroenterology 87: 338–343.
25. Ueno N, Inui A, Iwamoto M, Kaga T, Asakawa A, et al. (1999) Decreased food
intake and body weight in pancreatic polypeptide- overexpressing mice.
Gastroenterology 117: 1427–1432.
26. Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, et al. (2003)
Characterization of the effects of pancreatic polypeptide in the regulation of
energy balance. Gastroenterology 124: 1325–1336.
27. Parker RM, Herzog H (1999) Regional distribution of Y-receptor subtype
mRNAs in rat brain. European Journal of Neuroscience 11: 1431–1448.
28. Parker R, Herzog H (2000) Localization of Y-receptor subtype mRNAs in rat
brain by digoxigenin labeled in situ hybridization. Neuropeptide Y Protocols
153: 165–183.
29. McTigue DM, Hermann GE, Rogers RC (1997) Effect of pancreatic
polypeptide on rat dorsal vagal complex neurons. Journal of Physiology 499:
475–483.
30. Jobst EE, Enriori PJ, Cowley MA (2004) The electrophysiology of feeding
circuits. Trends Endocrinol Metab 15: 488–499.
31. Sainsbury A, Schwarzer C, Couzens M, Jenkins A, Oakes SR, et al. (2002) Y4
receptor knockout rescues fertility in ob/ob mice. Genes and Development 16:
1077–1088.
32. Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, et al. (2003) Acute
effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in
the mouse. Biochemical and Biophysical Research Communications 311:
915–919.
33. Sainsbury A, Schwarzer C, Couzens M, Fitissov S, Furtinger S, et al. (2002)
Important role of hypothalamic Y2 receptors in bodyweight regulation revealed
in conditional knockout mice. Proceedings of the National Academy of Sciences
of the United States of America 99: 8938–8943.
34. Franklin KB, Paxinos G (1997) The mouse brain in stereotaxic coordinates. San
Diego: Academic Press.
35. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, et al. (2007) Tumor-induced
anorexia and weight loss are mediated by the TGF-beta superfamily cytokine
MIC-1. Nat Med 13: 1333–1340.
36. Date Y, Shimbara T, Koda S, Toshinai K, Ida T, et al. (2006) Peripheral ghrelin
transmits orexigenic signals through the noradrenergic pathway from the
hindbrain to the hypothalamus. Cell Metab 4: 323–331.
37. McMinn JE, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW (2000) Effect
of intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos
induction, and neuropeptide expression. Am J Physiol Regul Integr Comp
Physiol 279: R695–703.
38. Horvath TL, Naftolin F, Leranth C (1992) GABAergic and catecholaminergic
innervation of mediobasal hypothalamic beta-endorphin cells projecting to the
medial preoptic area. Neuroscience 51: 391–399.
39. Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, et al. (2001) Leptin
activates anorexigenic POMC neurons through a neural network in the arcuate
nucleus. Nature 411: 480–484.
40. Vergoni AV, Bertolini A (2000) Role of melanocortins in the central control of
feeding. Eur J Pharmacol 405: 25–32.
41. Jegou S, Blasquez C, Delbende C, Bunel DT, Vaudry H (1993) Regulation of
alpha-melanocyte-stimulating hormone release from hypothalamic neurons.
Ann N Y Acad Sci 680: 260–278.
42. Smith MS (1993) Lactation alters neuropeptide-Y and proopiomelanocortin
gene expression in the arcuate nucleus of the rat. Endocrinology 133:
1258–1265.
43. Ellacott KL, Cone RD (2004) The central melanocortin system and the
integration of short- and long-term regulators of energy homeostasis. Recent
Prog Horm Res 59: 395–408.
44. Levi R, Seyedi N, Schaefer U, Estephan R, Mackins CJ, et al. (2007) Histamine
H3-receptor signaling in cardiac sympathetic nerves: Identification of a novel
MAPK-PLA2-COX-PGE2-EP3R pathway. Biochem Pharmacol 73:
1146–1156.
45. Mahon MJ, Bonacci TM, Divieti P, Smrcka AV (2006) A docking site for G
protein betagamma subunits on the parathyroid hormone 1 receptor supports
signaling through multiple pathways. Mol Endocrinol 20: 136–146.
46. Acuna-Goycolea C, Tamamaki N, Yanagawa Y, Obata K, van den Pol AN
(2005) Mechanisms of neuropeptide Y, peptide YY, and pancreatic polypeptide
inhibition of identified green fluorescent protein-expressing GABA neurons in
the hypothalamic neuroendocrine arcuate nucleus. J Neurosci 25: 7406–7419.
47. Halatchev IG, Ellacott KL, Fan W, Cone RD (2004) Peptide YY3-36 inhibits
food intake in mice through a melanocortin-4-receptor-independent mechanism.
Endocrinology 145: 2585–2590.
48. Wang C, Bomberg E, Levine A, Billington C, Kotz CM (2007) Brain-derived
neurotrophic factor in the ventromedial nucleus of the hypothalamus reduces
energy intake. Am J Physiol Regul Integr Comp Physiol 293: R1037–1045.
49. Inoue S, Nagase H, Satoh S, Saito M, Egawa M, et al. (1991) Role of the efferent
and afferent vagus nerve in the development of ventromedial hypothalamic
(VMH) obesity. Brain Res Bull 27: 511–515.
Y4, POMC, MC4 and PP in Satiety
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8488